Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Effects of Meditative Movement on Body Composition
Interventions: Meditative Movement; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Kidney Transplant Recipients, Liver Transplant Recipients
Interventions: Prograf, Tacrolimus; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Posture, Musculoskeletal Equilibrium, Electromyography, Kinematics
Interventions: Exercise Then Stretch, Stretch Then Exercise; Other
Lead sponsor: Radford University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Nausea and Vomiting, Chemotherapy-Induced
Interventions: ketoconazole, casopitant 100 mg, Casopitant 50 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy
Interventions: MK-6916, Diltiazem; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Asthma
Interventions: fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 3
States / cities: Gainesville, Florida • Iowa City, Iowa • Madison, Wisconsin

Conditions: Epilepsy, Alzheimer Disease, Epilepsy Intractable
Interventions: NPT 2042 (Reference formula/Formulation 1), NPT 2042 (Test formula/Formulation 2); Drug
Lead sponsor: NeuroPro Therapeutics, Inc.; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Adults
Interventions: KSP-910638G, 0.4 mg, KSP-910638G, 1.2 mg; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 25 Years to 100 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Pharmacokinetics
Interventions: PrimeC 748 mg, Ciprofloxacin 750 MG, Celecoxib 200mg; Drug
Lead sponsor: NeuroSense Therapeutics Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Barrett Esophagus, Esophageal Adenocarcinoma
Interventions: GI heptapeptide; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: HIV
Interventions: Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet), Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel), Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel); Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 195 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: San Francisco, California • Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Asthma
Interventions: Placebo, 90 mcg Reference Product, 180 mcg Reference Product, 90 mcg Test Product; Drug
Lead sponsor: Amneal Ireland Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Brookhaven, New York

Conditions: Healthy
Interventions: AVP-923, AVP-786, Itraconazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Adult Subjects
Interventions: Losmapimod 15 mg oral tablet, Losmapimod two 7.5 mg oral tablets, Losmapimod one 15 mg oral tablet; Drug
Lead sponsor: Fulcrum Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Primary Insomnia, Secondary Insomnia
Interventions: LY2624803, Placebo, zolpidem; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 49
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 46 more

Conditions: Advanced Cancer, Solid Tumors, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
Interventions: FN-1501; Drug
Lead sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Fairway, Kansas • Detroit, Michigan

Conditions: Arthritis, Rheumatoid; Arthritis, Psoriatic
Interventions: Commercial Formulation Etanercept, New Formulation Etanercept; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 29
States / cities: Birmingham, Alabama • El Cajon, California • Lomita, California + 26 more

Conditions: Healthy Volunteers
Interventions: Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Infection, Human Immunodeficiency Virus I
Interventions: GSK1349572, GSK2248761; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Asthma
Interventions: Indacaterol 27.5 mcg, Indacaterol 37.5, Indacaterol 55 mcg, Indacaterol 75 mcg, Indacaterol 150 mcg, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 12
States / cities: Huntington Beach, California • Los Angeles, California • Mission Viejo, California + 9 more

Conditions: Headache, Traumatic Brain Injury
Interventions: Traditional Chinese Acupuncture (TCA), Auricular (Ear) Acupuncture, Usual Care; Procedure · Other
Lead sponsor: Samueli Institute for Information Biology; Other
Eligibility: 18 Years to 69 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Alexandria, Virginia

Conditions: Visual Acuity
Interventions: ACUVUE Oasys 1-Day with HydraLuxe Technology for Astigmatism, ACUVUE Oasys 1-Day with HydraLuxe Technology; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 39 Years
Enrollment: 174 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 13
States / cities: Rocklin, California • Longwood, Florida • Maitland, Florida + 10 more

Conditions: Advanced Chronic Liver Disease, Healthy Participants
Interventions: AZD2389, Midazolam, Caffeine, Bupropion; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Ensifentrine 3 mg, Glycopyrrolate 42.5 mcg, Ensifentrine 1.5 mg, Ensifentrine 3 mg (marketed formulation); Drug
Lead sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 4
States / cities: Clearwater, Florida • Tampa, Florida • Saint Charles, Missouri + 1 more

Search by objective public record fields.

The Move Well Study

Pharmacokinetic Studies of Tacrolimus in Transplant Patients

Acute Responses of Postural Alignment, Kinematic Synergy, and Intermuscular Coherence to Postural Muscle Facilitation

Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]

A Study of the Effect of Multiple Doses of Diltiazem on the Plasma Levels of MK-6916 in Healthy Participants (MK-6916-005)

Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair

Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042

Study of the Safety of KSP Heptapeptide (KSP-910638G)

A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject

Esophageal Protocol for Detection of Neoplasia in the Digestive Tract

Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel

Bronchoprovocation Study to Evaluate the Pharmacodynamics of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base

Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts

Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets

An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia

A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML

Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis

Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult Volunteers

A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.

Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma

Exploratory Study to Evaluate 2 Acupuncture Methods for the Treatment of Headaches Associated With TBI

Clinical Evaluation of Spherical Soft Contact Lenses, Toric Soft Contact Lenses and Spectacles in Low Astigmats

A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease